Cargando…

APOBEC3B and CD274 as Combined Biomarkers for Predicting Response to Immunotherapy in Urothelial Carcinoma of the Bladder

Immunotherapy has become a promising form of treatment for cancers. There is a need to predict response to immunotherapy accurately. In the UCSC Xena, pan-cancer analysis revealed a positive relationship between APOBEC3B (A3B) and tumor mutational burden (R = 0.28, P < 0.001) and microsatellite i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Chuanhao, Cheng, Zhichao, Wang, Zhe, Zhao, Genghao, Yuan, Yonghui, Wang, Ruoyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557251/ https://www.ncbi.nlm.nih.gov/pubmed/36245972 http://dx.doi.org/10.1155/2022/6042334

Ejemplares similares

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

Risk Model and Immune Signature of m7G-Related lncRNA Based on Lung Adenocarcinoma
por: Zhang, Chuanhao, et al.
Publicado: (2022)

CD10 expression in urothelial carcinoma of the bladder
por: Bahadir, Burak, et al.
Publicado: (2009)

Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma
por: Kang, So Young, et al.
Publicado: (2022)

Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD‐L1 (CD274)‐expression: Possible roles of tumour micro environmental factors for CD274 expression
por: Inaguma, Shingo, et al.
Publicado: (2017)

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer
por: Olah, Csilla, et al.
Publicado: (2022)

Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?
por: Kumar, Naveen
Publicado: (2021)

Immune escape mechanisms and immunotherapy of urothelial bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021)

Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy
por: Kim, Ryul, et al.
Publicado: (2022)

Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy
por: Fabrizio, Federico Pio, et al.
Publicado: (2018)

EIF2S2 is a novel independent prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma
por: Liu, Jing, et al.
Publicado: (2022)

Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma
por: Liang, Fangfang, et al.
Publicado: (2021)

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
por: Renner, Alex, et al.
Publicado: (2021)

Combined Genetic Biomarkers Confer Susceptibility to Risk of Urothelial Bladder Carcinoma in a Saudi Population
por: Elhawary, Nasser Attia, et al.
Publicado: (2017)

Prognostic Value of HPV E6 and APOBEC3B in Upper Urinary Tract Urothelial Carcinoma
por: He, Le, et al.
Publicado: (2022)

Urothelial Bladder Cancer Urinary Biomarkers
por: Noon, Aidan P, et al.
Publicado: (2014)

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016)

Protein Profiling of Bladder Urothelial Cell Carcinoma
por: Hu, Jinghai, et al.
Publicado: (2016)

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
por: Bevers, R F M, et al.
Publicado: (2004)

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
por: Kacew, Alec, et al.
Publicado: (2020)

Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder
por: Li, Yu, et al.
Publicado: (2021)

Functional Genomics Profiling of Bladder Urothelial Carcinoma MicroRNAome as a Potential Biomarker()
por: Li, Wei Tse, et al.
Publicado: (2018)

Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer
por: Humayun-Zakaria, Nada, et al.
Publicado: (2019)

Infiltration of a Unique CD8(+)CD274(+) Cell Subgroup in Hepatocellular Carcinoma is Associated with Poor Clinical Outcomes
por: Zhang, Yong, et al.
Publicado: (2023)

Immunotherapy With Bacillus Calmette-Guerin (BCG) in a 16-Year-Old With Urothelial Bladder Carcinoma
por: Martinez-Thomas, Jose M, et al.
Publicado: (2022)

Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
por: Guo, Ya, et al.
Publicado: (2022)

Integrated proteogenomic characterization of urothelial carcinoma of the bladder
por: Xu, Ning, et al.
Publicado: (2022)

Intravesical therapy for urothelial carcinoma of the bladder
por: Manoharan, M.
Publicado: (2011)

Role of angiogenesis in urothelial bladder carcinoma
por: Fus, Łukasz Piotr, et al.
Publicado: (2016)

Bladder melanosis with concurrent urothelial carcinoma
por: Yau, Susanna E., et al.
Publicado: (2017)

Cutaneous metastasis of bladder urothelial carcinoma
por: Hasan, Osamah, et al.
Publicado: (2019)

Giant Cell Urothelial Carcinoma of Bladder
por: Wijesinghe, Harshima Disvini, et al.
Publicado: (2021)

Molecular classification of urothelial bladder carcinoma
por: Schwarzova, Lucia, et al.
Publicado: (2023)

Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy
por: Tang, Qi, et al.
Publicado: (2023)

Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma
por: Zeng, Shuxiong, et al.
Publicado: (2017)

The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma
por: Wan, Zhengqiang, et al.
Publicado: (2023)

Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder
por: McNeil, Brian K, et al.
Publicado: (2014)

PLAUR as a Potential Biomarker Associated with Immune Infiltration in Bladder Urothelial Carcinoma
por: Liu, Mulin, et al.
Publicado: (2021)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response
por: Daro-Faye, Mame, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j69v22dqr1th9uhgmbu6nmb8f7